AU2010200611B8 - Nucleic acids and proteins from streptococcus groups A and B - Google Patents
Nucleic acids and proteins from streptococcus groups A and B Download PDFInfo
- Publication number
- AU2010200611B8 AU2010200611B8 AU2010200611A AU2010200611A AU2010200611B8 AU 2010200611 B8 AU2010200611 B8 AU 2010200611B8 AU 2010200611 A AU2010200611 A AU 2010200611A AU 2010200611 A AU2010200611 A AU 2010200611A AU 2010200611 B8 AU2010200611 B8 AU 2010200611B8
- Authority
- AU
- Australia
- Prior art keywords
- protein
- antigen
- nucleic acid
- sequence
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract 37
- 150000007523 nucleic acids Chemical class 0.000 title claims 18
- 108020004707 nucleic acids Proteins 0.000 title claims 14
- 102000039446 nucleic acids Human genes 0.000 title claims 14
- 241000194017 Streptococcus Species 0.000 title claims 5
- 108091005461 Nucleic proteins Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract 36
- 102000036639 antigens Human genes 0.000 claims abstract 26
- 108091007433 antigens Proteins 0.000 claims abstract 26
- 239000000427 antigen Substances 0.000 claims abstract 24
- 239000000203 mixture Substances 0.000 claims abstract 13
- 241000193985 Streptococcus agalactiae Species 0.000 claims abstract 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 9
- 230000002163 immunogen Effects 0.000 claims abstract 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims 10
- 230000000295 complement effect Effects 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 201000009906 Meningitis Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 159000000013 aluminium salts Chemical class 0.000 claims 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 241000605862 Porphyromonas gingivalis Species 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 239000004147 Sorbitan trioleate Substances 0.000 claims 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000037798 influenza B Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- -1 polyoxyethylene Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 235000019337 sorbitan trioleate Nutrition 0.000 claims 1
- 229960000391 sorbitan trioleate Drugs 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 abstract 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 abstract 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
Abstract
The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
Description
Editorial Note for 2010200611 This application has Description of 3028 pages on CD, which is available on request from IP Australia.
Claims (31)
1. An immunogenic S. agalactiae protein in substantially pure form comprising a fragment of 100 or more consecutive amino acids from the amino acid sequence SEQ ID 5 NO: 3746, wherein the protein binds to specific antibodies raised against an S. agalactiae protein comprising the amino acid sequence SEQ ID NO: 3746, wherein the specific antibodies do not bind to unrelated antigens, and wherein the immunogenic S. agalactiae protein is an isolated protein or a recombinant protein. 10
2. The immunogenic S. agalactiae protein of claim I which is the isolated protein.
3. The immunogenic S. agalactiae protein of claim 1 which is the recombinant protein. 15
4. An isolated protein comprising an amino acid sequence of SEQ ID NO: 3746.
5. An isolated protein having 70% or greater sequence identity to the protein according to claim 4. 20
6. A composition comprising: an isolated immunogenic S. agalactiae protein in substantially pure form comprising a fragment of 100 or more consecutive amino acids from the amino acid sequence SEQ ID NO: 3746, wherein the protein binds to specific antibodies raised against an S. agalactiae protein comprising the amino acid sequence SEQ ID 25 NO: 3746, wherein the specific antibodies do not bind to unrelated antigens; and an adjuvant.
7. A composition comprising: a recombinant immunogenic S. agalactiae protein comprising a fragment of 30 100 or more consecutive amino acids from the amino acid sequence SEQ ID 3025 NO:3746, wherein the protein binds to specific antibodies raised against an S. agalactiae protein comprising the amino acid sequence SEQ ID NO:3746, wherein the specific antibodies do not bind to unrelated antigens; and an adjuvant. 5
8. The composition of claim 6 or 7, which comprises a pharmaceutically acceptable carrier.
9. The composition of any one of claims 6 to 8, wherein the adjuvant comprises an 10 aluminium salt.
10. The composition of claim 9, wherein the aluminium salt is alum.
11. The composition of claim 6 or 7, wherein the adjuvant comprises squalene, 15 polyoxyethylene 80 sorbitan monooleate, and sorbitan trioleate.
12. An isolated antibody that binds to the protein according to any one of claims I to 5.
13. The antibody according to claim 12, wherein said antibody is a monoclonal 20 antibody, a chimeric antibody, a humanized antibody or a fully human antibody.
14. An isolated nucleic acid molecule which encodes a protein according to any one of claims 1 to 5. 25
15. An isolated nucleic acid molecule comprising a fragment of 100 or more consecutive nucleotides from the nucleic acid sequence SEQ ID NO: 3745.
16. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 3745 or a sequence having 70% or greater sequence identity to the nucleic acid 30 sequence of SEQ ID NO: 3745. 3026
17. An isolated nucleic acid molecule comprising a nucleotide sequence complementary to the nucleic acid molecule according to any one of claims 14 to 16. 5
18. An isolated nucleic acid molecule which can hybridise to a nucleic acid molecule according to any one of claims 14 to 16 under high stringency conditions.
19. Use of a composition according to any one of claims 6 to I I in the manufacture of a medicament for the treatment or prevention of infection or disease caused by a 10 Streptococcus bacterium.
20. The use according to claim 19, wherein the Streptococcus bacterium is S agalactiae or Spyrogenes. 15
21. A method of treating a patient for an infection or disease caused by a Streptococcus bacteria, comprising administering to the patient a therapeutically effect amount of the composition of any one of claims 6 to 11.
22. A hybrid protein represented by the formula NH 2 -A-[-X-L-],-B-COOH, wherein X 20 is an amino acid sequence as defined in claim 1, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1.
23. A kit comprising primers for amplifying a nucleic acid sequence according to any 25 one of claims 14 to 16, the kit comprising a first primer and a second primer, wherein the first primer is substantially complementary to said template sequence and the second primer is substantially complementary to a complement of said template sequence, wherein the parts of said primers which have substantial complementarity define the termini of the template sequence to be amplified. 30 3027
24. A kit comprising first and second single-stranded oligonucleotides which allow amplification of the nucleic acid molecule according to any one of claims 14 to 16 in a single- or double-stranded nucleic acid molecule (or mixture thereof), wherein: (a) the first oligonucleotide comprises a primer sequence which is substantially 5 complementary to said template nucleic acid sequence; (b) the second oligonucleotide comprises a primer sequence which is substantially complementary to the complement of said template nucleic acid sequence; (c) the first oligonucleotide and/or second oligonucleotide comprise(s) sequence which is not complementary to said template nucleic acid; and 10 (d) said primer sequences define the termini of the template sequence to be amplified.
25. The kit of claim 24, wherein the non-complementary sequence(s) of (c) comprise a restriction site and/or promoter sequence. 15
26. A process for detecting Streptococcus in a biological sample, comprising the step of contacting nucleic acid according to any one of claims 14 to 16 with a biological sample obtained from a subject under hybridising conditions.
27. A method of producing the protein according to claim 1, 3, 4 or 5, which method 20 comprises providing an expression system for the nucleotide sequence according to claim 14 to a recombinant system for expression of said nucleotide sequence and effecting the expression of said nucleotide sequence to produce said protein.
28. A method for isolating a compound which binds to the protein according to any one 25 of claims I to 5, which method comprises contacting the protein produced by the method of claim 27 with a candidate compound; assessing the ability of said protein to interact with or bind said candidate compound, assessing the ability of said protein to interact with or bind said candidate compound, assessing the ability of said protein to interact with or bind said candidate compound; and isolating as a successful candidate a compound that 30 interacts with or binds said protein.
29. A composition comprising a protein according to any one of claims I to 5 and one or more of the following antigens: i. a protein antigen from Helicobacterpylori; 3028 ii. a protein antigen from N. meningitides serogroup B; iii. an outer membrane vesicle (OMV) preparation from N. meningitides serogroup B; iv. a saccharide antigen from N meningitides serogroup A, C, W135 and/or Y; 5 v. a saccharide antigen from Streptococcuspneumoniae; vi. an antigen from hepatitis A virus; vii. an antigen from hepatitis B virus; viii. an antigen from hepatitis C virus; ix. an antigen from Bordetella pertussis; 10 x. a diphtheria antigen; xi. a tetanus antigen; xii. a saccharide antigen from Haemophilus influenza B; xiii. an antigen from Ngonorrhoeae; xiv. an antigen from Chlamydiapneumoniae; 15 xv. an antigen from Chlamydia trachomatis; xvi. an antigen from Porphyromonas gingivalis; xvii. polio antigen(s); xviii. rabies antigen(s); xix. measles, mumps and/or rubella antigen(s); 20 xx. influenza antigen(s); xxi. an antigen from Moraxella catarrhalis; and/or an antigen from Staphylococcus aureus.
30. A composition comprising two or more proteins, wherein each protein is a protein 25 according to any one of claims I to 5.
31. A protein according to claim 1, a composition according to claim 6 or 7 or 29, an antibody according to claim 12, a nucleic acid molecule according to claim 14 or 15, a use according to claim 19, a method according to claim 21, a kit according to claim 23 or 24, a 30 process according to claim 26, or a method according to claim 27 or 28, substantially as herein described with reference to any one or more of the Figures and/or Examples, excluding comparative Examples.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010200611A AU2010200611B8 (en) | 2000-10-27 | 2010-02-10 | Nucleic acids and proteins from streptococcus groups A and B |
| AU2012200299A AU2012200299B2 (en) | 2000-10-27 | 2012-01-18 | Nucleic acids and proteins from streptococcus groups A and B |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0026333.5 | 2000-10-27 | ||
| GB0028727.6 | 2000-11-24 | ||
| GB0105640.7 | 2001-03-07 | ||
| AU2002214127A AU2002214127B2 (en) | 2000-10-27 | 2001-10-29 | Nucleic acids and proteins from streptococcus groups A and B |
| AU2004226909A AU2004226909B2 (en) | 2000-10-27 | 2004-11-02 | Nucleic acids and proteins from streptococcus groups A & B |
| AU2008200977A AU2008200977B2 (en) | 2000-10-27 | 2008-02-28 | Nucleic acids and proteins from streptococcus groups A & B |
| AU2010200611A AU2010200611B8 (en) | 2000-10-27 | 2010-02-10 | Nucleic acids and proteins from streptococcus groups A and B |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008200977A Division AU2008200977B2 (en) | 2000-10-27 | 2008-02-28 | Nucleic acids and proteins from streptococcus groups A & B |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012200299A Division AU2012200299B2 (en) | 2000-10-27 | 2012-01-18 | Nucleic acids and proteins from streptococcus groups A and B |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010200611A1 AU2010200611A1 (en) | 2010-03-18 |
| AU2010200611B2 AU2010200611B2 (en) | 2011-10-20 |
| AU2010200611B8 true AU2010200611B8 (en) | 2011-11-03 |
Family
ID=42045294
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004226909A Ceased AU2004226909B2 (en) | 2000-10-27 | 2004-11-02 | Nucleic acids and proteins from streptococcus groups A & B |
| AU2010200611A Ceased AU2010200611B8 (en) | 2000-10-27 | 2010-02-10 | Nucleic acids and proteins from streptococcus groups A and B |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004226909A Ceased AU2004226909B2 (en) | 2000-10-27 | 2004-11-02 | Nucleic acids and proteins from streptococcus groups A & B |
Country Status (1)
| Country | Link |
|---|---|
| AU (2) | AU2004226909B2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846547A (en) * | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
-
2004
- 2004-11-02 AU AU2004226909A patent/AU2004226909B2/en not_active Ceased
-
2010
- 2010-02-10 AU AU2010200611A patent/AU2010200611B8/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010200611B2 (en) | 2011-10-20 |
| AU2004226909B2 (en) | 2008-02-07 |
| AU2010200611A1 (en) | 2010-03-18 |
| AU2004226909A8 (en) | 2004-11-25 |
| AU2004226909A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002214127B2 (en) | Nucleic acids and proteins from streptococcus groups A and B | |
| RU2004110230A (en) | HYBRID AND TANDEMIC EXPRESSION OF NEISSERY PROTEINS | |
| CA2438080A1 (en) | Gonococcal proteins and nucleic acids | |
| AU2001239478B2 (en) | Hybrid expression of neisserial proteins | |
| RU2006144093A (en) | POLYPEPTIDES UNPRECIPABLE HAEMOPHILUS INFLUENZAE | |
| JP2008538183A5 (en) | ||
| US10634685B2 (en) | Pneumococcal serotypes | |
| JP5285431B2 (en) | Streptococcus pneumoniae serotype | |
| JP2008521385A (en) | CpG-containing single-stranded deoxynucleotides as adjuvants | |
| JPH10504444A (en) | Vaccine against Moraxella catarrhalis | |
| JP2012516155A (en) | Thermophilic helicase-dependent amplification technique using endpoint homogeneous fluorescence detection | |
| WO2015084846A1 (en) | High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides | |
| JPH06233699A (en) | Method and reagent for listeriosis detection | |
| US7618635B2 (en) | Super-antigen fusion proteins and the use thereof | |
| AU2010200611B8 (en) | Nucleic acids and proteins from streptococcus groups A and B | |
| JP4196236B2 (en) | Nucleic acid amplification reagent and sequence-specific nucleic acid amplification method | |
| AU2012200299B2 (en) | Nucleic acids and proteins from streptococcus groups A and B | |
| JP6069314B2 (en) | Large-scale synthesis method of long nucleic acid molecules | |
| WO2018084562A1 (en) | Method for producing dextran polymer-based, amplified nucleic acid aptamer nanoconstruct selectively capturing target molecule | |
| JP5704916B2 (en) | Streptococcus pneumoniae serotype 6D | |
| RU2223492C2 (en) | Protein obtained from neisseria meningitidis (variants, its fragment, nucleic acid encoding thereof (variants), probe, primer, composition | |
| CN106084037B (en) | Bacillus anthracis capsule surface trisaccharide conjugate and preparation method and application thereof | |
| AU2009230776B2 (en) | Neisseria meningitidis antigens and compositions | |
| KR930010768B1 (en) | Dna for rickettsia tsutsugamushi | |
| JP2001515710A (en) | Nucleic acid sequences and methods for detecting bacteria of the genus Pseudomonas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: J. CRAIG VENTER INSTITUTE, INC.; NOVARTIS VACCINES Free format text: FORMER APPLICANT(S): J. CRAIG VENTER INSTITUTE, INC.; NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. |
|
| TH | Corrigenda |
Free format text: IN VOL 25, NO 41, PAGE(S) 5197 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME J. CRAIG VENTER INSTITUTE, INC.; NOVARTIS VACCINES AND DIAGNOSTICS, INC., APPLICATION NO. 2010200611, UNDER INID (72) ADD CO-INVENTOR SCARSELLI, MARIA; DELETE CO-INVENTOR MARGARIT Y ROS, IMMACULADA |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |